5-TFMO-DMT (5-(trifluoromethoxy)-DMT, 5-OCF3-DMT, 5-(trifluoromethoxy)-N,N-dimethyltryptamine) is a psychedelic tryptamine derivative related to drugs such as 5-MeO-DMT and DMT (DMT). It acts as an agonist at the 5-HT2A receptor with an EC50 of 127.2 nM.[1] It was shown to release serotonin (5-HT) from synaptosomal preparations, and to reduce immobility time in the forced-swim test in animal studies, suggesting that it might have antidepressant activity.[1]

5-(Trifluoromethoxy)-DMT
Clinical data
Other names5-OCF3-DMT
Identifiers
  • N,N-dimethyl-5-(trifluoromethoxy)-1H-Indole-3-ethanamine
CAS Number
PubChem CID
Chemical and physical data
FormulaC13H15F3N2O
Molar mass272.271 g·mol−1
3D model (JSmol)
  • CN(C)CCC1=CNC2=CC=C(OC(F)(F)F)C=C21
  • InChI=InChI=1S/C13H15F3N2O/c1-18(2)6-5-9-8-17-12-4-3-10(7-11(9)12)19-13(14,15)16/h3-4,7-8,17H,5-6H2,1-2H3
  • Key:ODQYGFDOWUZNBA-UHFFFAOYSA-N

See also

edit

References

edit
  1. ^ a b WO 2022/235927, Kruegel AC, "NOVEL TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS.", published 10 November 2022, assigned to Gilgamesh Pharmaceuticals, Inc..